Gene silencing by DNA methylation in haematological malignancies
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: The past decade has seen an explosion of interest in the epigenetics of cancer, with an increasing understanding that this form of genomic modification plays a critical role in pathogenesis. The malignant phenotype results from a step‐wise increase of both genetic abnormalities and epigenetic modifications, leading to dysregulation of critical genes controlling cell growth, differentiation and apoptosis. The methylation of CpG islands within gene promoters is a major epigenetic transcriptional control mechanism that is frequently dysregulated in human cancer. This phenomenon (methylation of CpG islands) plays a critical role in the transcriptional silencing of tumour suppressor genes in cancer and has prompted the development and testing of several demethylating agents aimed at reversing this process. Clinical trials using epigenetically targeted therapies have yielded particularly promising results in the myelodysplastic syndromes (MDS), in which tumour suppressor gene silencing by promoter methylation is a frequent event. Several genes and gene pathways disrupted by aberrant CpG island methylation have now been identified in haematological malignancies, the most frequently studied being the cell cycle inhibitors p16 (now termed CDKN2A; mostly methylated in lymphoid malignancy) and p15 (now termed CDKN2B; commonly methylated in lymphoid and myeloid malignancies). This review will discuss the role that aberrant gene silencing by promoter hypermethylation plays in the molecular pathogenesis of haematological malignancies and assess the clinical potential of demethylating agents for the management of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124 · cited 3×
“DNA methylation in normal and cancer cells DNA methylation, catalysed by DNA methyltransferase, involves the addition of a methyl group to the carbon 5 position of the cytosine ring in the CpG dinucleotide and results in the formation of methylcytosine (Holliday & Grigg, 1993; Bird, 2002).”
BackgroundInfluentialThe fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Histone acetylation and transcriptional regulatory mechanisms
Struhl, K. (1998) · Genes & Development · doi:10.1101/gad.12.5.599 · Cited by 1,815 · cited 2×
“Hypermethylated and silenced genes in cancer are known to have key histone modifications associated with their promoter regions (Struhl, 1998).”
BackgroundThe C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia
Agrawal, S., Hofmann, W.-K., Tidow, N., Ehrich, M., Boom, D. V. D., Koschmieder, S., Berdel, W. E., Serve, H., & Müller-Tidow, C. (2007) · Blood · doi:10.1182/blood-2006-08-040147 · Cited by 119 · cited 2×
“A further interesting report by the same group suggests that DNA methylation of tumour suppressor genes in clinical remission might enable prediction of the relapse risk in AML (Agrawal et al, 2007b).”
Background
Cited by
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
Jiang, Y., Dunbar, A., Gondek, L. P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y., & Maciejewski, J. P. (2009) · Blood · doi:10.1182/blood-2008-06-163246 · Cited by 384
Epigenetic regulation of the INK4b-ARF-INK4a locus: In sickness and in health
Popov, N., & Gil, J. (2010) · Epigenetics · doi:10.4161/epi.5.8.12996 · Cited by 202
Cancer Chemoprevention and Nutri-Epigenetics: State of the Art and Future Challenges
Gerhauser, C. (2012) · Topics in Current Chemistry · doi:10.1007/128_2012_360 · Cited by 194
“Hypermethylation of the p16 promoter is frequently observed in all major human malignancies, including hepatocellular carcinoma, primary gastric carcinoma, Barrett’s esophagus and esophageal adenocarcinoma [214], breast cancer [215], squamous cell carcinoma of the lung [216], colorectal cancer [217], lymphoma [218], a…”
BackgroundA Comprehensive Microarray-Based DNA Methylation Study of 367 Hematological Neoplasms
Martin-Subero, J. I., Ammerpohl, O., Bibikova, M., Wickham-Garcia, E., Agirre, X., Alvarez, S., Brüggemann, M., Bug, S., Calasanz, M. J., Deckert, M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006986 · Cited by 134
Rb intrinsically promotes erythropoiesis by coupling cell cycle exit with mitochondrial biogenesis
Sankaran, V. G., Orkin, & Walkley, C. R. (2008) · Genes & Development · doi:10.1101/gad.1627208 · Cited by 133
“The molecular basis of MDS is not well understood, although the most common known abnormality involves epigenetic silencing of CDKN2B (Boultwood and Wainscoat 2007), a key negative regulator of the cell cycle.”
Background
Metadata
- Authors
- Boultwood, J., & Wainscoat, J. S.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2007-05-09
- Volume
- 138
- Issue
- 1
- Pages
- 3-11
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1994281469
- Cited by
- 145
- References
- 4
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene silencing by DNA methylation in haematological malignancies. https://app.cochat.ai/papers/10.1111/j.1365-2141.2007.06604.x
- The paper
- Boultwood, J., & Wainscoat, J. S. (2007). Gene silencing by DNA methylation in haematological malignancies. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2007.06604.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.